Lupus erythematosus - Lupus Eritematozus
☆ AI Dermatology — Free Service
U rezultatima Stiftung Warentest-a za 2022. iz Njemačke, zadovoljstvo potrošača ModelDerm-om bilo je samo nešto niže nego s plaćenim telemedicinskim konsultacijama.
U rezultatima Stiftung Warentest-a za 2022. iz Njemačke, zadovoljstvo potrošača ModelDerm-om bilo je samo nešto niže nego s plaćenim telemedicinskim konsultacijama.
Izgleda kao blagi ljubičasti eritem.
Leptirni osip obično se pojavljuje na licu.
relevance score : -100.0%
ReferencesIdentificiranje i klasifikacija cutaneous lupus erythematosus (CLE) postavlja dijagnostičke izazove i razlikuje ga od systemic lupus erythematosus s zahvaćenošću kože. Nedavne studije bacaju svjetlo na genetske, okolišne i imunološke faktore koji su u osnovi CLE. Indukcija lijekovima posebno se pojavila kao jedan od najvažnijih pokretača CLE‑a. Liječenje uključuje lokalne i sistemske terapije, uključujući obećavajuće biološke lijekove poput belimumab, rituximab, ustekinumab, anifrolumab i BIIB059, s dokazanom djelotvornošću u kliničkim ispitivanjima.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) pokriva različite kožne probleme, od kojih neki mogu biti povezani sa širim zdravstvenim problemima. Kategoriziran je u različite tipove, kao što su akutni CLE (ACLE), subakutni CLE (SCLE) i kronični CLE (CCLE). CCLE se sastoji od discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus i lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus je grupa autoimunih bolesti koje mogu zahvatiti različite dijelove tijela. Neki tipovi, poput systemic lupus erythematosus (SLE), utiču na više organa, dok drugi, poput cutaneous lupus erythematosus (CLE), uglavnom utiču na kožu. Kategoriziramo različite vrste CLE na osnovu kombinacije kliničkih znakova, pregleda tkiva i krvnih testova, ali postoji mnogo varijacija među pojedincima. Problemi s kožom često nastaju zbog faktora poput izlaganja sunčevoj svjetlosti, pušenja ili određenih lijekova.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Uzrok Lupus Eritematozus (Lupus erythematosus) nije jasan. Među jednojajčanim blizancima, ako je jedan pogođen, postoji 24 % šanse da i drugi bude pogođen. Ženski spolni hormoni, sunčeva svjetlost, pušenje, nedostatak vitamina D i određene infekcije također povećavaju rizik.
Tretmani mogu uključivati NSAID, kortikosteroide, imunosupresive, hidroksihlorokin i metotreksat. Iako su kortikosteroidi efikasni, dugotrajna upotreba dovodi do nuspojava.